What Is It, and Why Does It Matter? Linzess (linaclotide) is a prescription once-daily oral medicine used to treat certain types of constipation, including those with no known cause and those related ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Linzess, the first therapy for pediatric functional constipation in patients aged 6 to 17 ...

– Expanded indication extends availability to children ages 2-5 with FC; previously approved in pediatric patients 6 years of age and older – – LINZESS remains the first-and-only FDA-approved ...

The U.S. Food and Drug Administration approved Linzess (linaclotide) as a once-daily treatment for pediatric patients ages 6 to 17 years with functional constipation. The approval was based on data ...

We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc.

Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), has witnessed a strong uptake in recent times.

Ironwood Pharmaceuticals (IRWD) announced on Wednesday that the Food and Drug Administration approved a label expansion for its AbbVie (ABBV)-partnered bowel disorder therapy Linzess to treat children ...

FDA has announced it has approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults, according to a news release. Linzess ...

Linzess is a prescription medication used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). It works by increasing fluid in the intestines and ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted priority review to a supplemental new drug application for Linzess for the treatment of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today ...